These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31825346)

  • 1. [New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora].
    Dibirov MD; Khachatryan NN; Isaev AI; Karsotyan GS; Alimova EE; Kostyuk EA
    Khirurgiia (Mosk); 2019; (12):74-83. PubMed ID: 31825346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 7. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
    Durand CR; Alsharhan M; Willett KC
    Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria.
    Adámková V
    Rozhl Chir; 2019; 98(4):145-151. PubMed ID: 31159547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
    Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
    Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
    Buckman SA; Krekel T; Muller AE; Mazuski JE
    Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
    Syue LS; Chen YH; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.